Insider Trades
Common-stock transactions that officers, directors and 10% owners of healthcare companies report to the SEC on Form 4, from 2006 to today, newest first.
Insider filings are public records and are not a recommendation.
Results
13 transactions, newest first
| Date | Insider | Relationship | Company | Transaction | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|---|---|
| Bodenhoff Mads | SVP & PAO | Ascendis Pharma A/SASND | SellS · Open-market or private sale | 3,000 | $270.19 | $810,570 | 0Direct | Form 4 filed 9 Sep 2026, on sec.gov (opens in a new tab)Filed 9 Sep 2026 | |
| Bodenhoff Mads | SVP & PAO | Ascendis Pharma A/SASND | OtherM · Option or derivative exercised or converted | 3,000 | $110.00 | $330,000 | 3,000Direct | Form 4 filed 9 Sep 2026, on sec.gov (opens in a new tab)Filed 9 Sep 2026 | |
| HOLTUG LARS | Director | Ascendis Pharma A/SASND | SellS · Open-market or private sale | 236 | $264.13 | $62,334.68 | 4,000Direct | Form 4 filed 3 Sep 2026, on sec.gov (opens in a new tab)Filed 3 Sep 2026 | |
| BIENAIME JEAN JACQUES | Director | Ascendis Pharma A/SASND | BuyP · Open-market or private purchase | 900 | $246.91 | $222,219 | 2,900Direct | Form 4 filed 18 Aug 2026, on sec.gov (opens in a new tab)Filed 18 Aug 2026 | |
| BIENAIME JEAN JACQUES | Director | Ascendis Pharma A/SASND | BuyP · Open-market or private purchase | 1,100 | $245.85 | $270,435 | 2,000Direct | Form 4 filed 18 Aug 2026, on sec.gov (opens in a new tab)Filed 18 Aug 2026 | |
| SMITH SCOTT THOMAS | EVP & Chief Financial Officer | Ascendis Pharma A/SASND | BuyP · Open-market or private purchase | 100 | $219.00 | $21,900 | 4,367Direct | Form 4 filed 2 Jun 2026, on sec.gov (opens in a new tab)Filed 2 Jun 2026 | |
| SMITH SCOTT THOMAS | EVP & Chief Financial Officer | Ascendis Pharma A/SASND | BuyP · Open-market or private purchase | 250 | $223.32 | $55,830 | 4,267Direct | Form 4 filed 1 Jun 2026, on sec.gov (opens in a new tab)Filed 1 Jun 2026 | |
| BIENAIME JEAN JACQUES | Director | Ascendis Pharma A/SASND | BuyP · Open-market or private purchase | 100 | $223.50 | $22,350 | 900Direct | Form 4 filed 1 Jun 2026, on sec.gov (opens in a new tab)Filed 1 Jun 2026 | |
| BIENAIME JEAN JACQUES | Director | Ascendis Pharma A/SASND | BuyP · Open-market or private purchase | 200 | $222.30 | $44,460 | 800Direct | Form 4 filed 1 Jun 2026, on sec.gov (opens in a new tab)Filed 1 Jun 2026 | |
| BIENAIME JEAN JACQUES | Director | Ascendis Pharma A/SASND | BuyP · Open-market or private purchase | 200 | $223.76 | $44,752 | 600Direct | Form 4 filed 1 Jun 2026, on sec.gov (opens in a new tab)Filed 1 Jun 2026 | |
| BIENAIME JEAN JACQUES | Director | Ascendis Pharma A/SASND | BuyP · Open-market or private purchase | 200 | $239.37 | $47,874 | 400Direct | Form 4 filed 27 May 2026, on sec.gov (opens in a new tab)Filed 27 May 2026 | |
| BIENAIME JEAN JACQUES | Director | Ascendis Pharma A/SASND | BuyP · Open-market or private purchase | 200 | $236.24 | $47,248 | 200Direct | Form 4 filed 27 May 2026, on sec.gov (opens in a new tab)Filed 27 May 2026 | |
| JENSEN FLEMMING STEEN | See Remarks | Ascendis Pharma A/SASND | SellS · Open-market or private sale | 19,460 | $238.49 | $4,641,015.40 | 0Direct | Form 4 filed 12 May 2026, on sec.gov (opens in a new tab)Filed 12 May 2026 |
Source: SEC EDGAR Form 4 filings and the SEC Insider Transactions Data Sets (2006 onward). Each row links to its Form 4 filing. Values are shares times the reported price. Nothing here is investment advice.